mRNA CDMO Arcalis Aims for One Stop Provider for Seed Verification, R&D, Commercial Production

May 31, 2021
Axcelead President Tomoyuki Fujisawa Arcalis, a CDMO specializing in mRNA drugs, will construct a new plant in Fukushima Prefecture, which is scheduled to launch drug substance production in 2023, Tomoyuki Fujisawa, president of Axcelead, which has a stake in the...read more